

Filed on behalf of: Corcept Therapeutics, Inc.

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC.,
Petitioner

v.

CORCEPT THERAPEUTICS, INC.,
Patent Owner

Case PGR2019-00048
U.S. Patent No. 10,195,214

PATENT OWNER PRELIMINARY RESPONSE

Table of Contents

	<u>Page</u>
I. INTRODUCTION	1
II. THE BOARD SHOULD DENY THE PETITION UNDER 35 U.S.C. § 324(A) BECAUSE PARALLEL DISTRICT COURT LITIGATION RENDERS INSTITUTION INEFFICIENT.....	5
III. THE BOARD SHOULD DENY INSTITUTION BECAUSE PETITIONER DOES NOT DEMONSTRATE A REASONABLE LIKELIHOOD THAT ANY CHALLENGED CLAIM WOULD HAVE BEEN OBVIOUS	9
A. The State of the Art and the '214 Patent	9
1. Cushing's Syndrome is a Debilitating and Difficult-to-Treat Disorder	9
2. Korlym® (Mifepristone) Is a First-in-Class Glucocorticoid Receptor Antagonist with a Complex Pharmacokinetic Profile.....	10
3. Patients with Cushing's Syndrome Often Take Multiple Drugs, Including Strong CYP3A Inhibitors	13
4. The Dangers of Concomitantly Administering Mifepristone and Strong CYP3A Inhibitors Were Well-Known in the Art.....	16
5. Because of these Known Dangers, the Art Taught to Never Administer More Than 300 mg of Mifepristone in Combination With a Strong CYP3A Inhibitor	20
6. Patent Owner Unexpectedly Found That 600 mg Mifepristone Could Safely and Effectively Be Dosed in Combination With Strong CYP3A Inhibitors.....	23
B. Scope and Content of the Asserted References	28
1. 2012 Korlym Label	28

2.	Lee.....	30
3.	2006 FDA Guidance	32
C.	Level of Ordinary Skill in the Art.....	35
D.	Claim Construction.....	35
E.	Petitioner Does Not Demonstrate a Reasonable Likelihood of Success on Ground 1	35
1.	The Petition Fails to Establish a Reasonable Expectation of Success.....	36
2.	Petitioner’s Invocation of “Routine Optimization” Does Not Provide the Missing Reasonable Expectation of Success	39
a.	Petitioner’s “Routine Optimization” Argument Ignores the Teaching Away in the Prior Art	41
b.	Petitioner’s “Routine Optimization” Argument Ignores the Well-Known Safety Concerns Associated With Both Mifepristone and Strong CYP3A Inhibitors Disclosed in the Art.....	45
c.	The FDA’s Requirement that Patent Owner Carry Out Additional Drug-Drug Interaction Studies as Part of the Korlym® Approval Process Does Not Provide a Reasonable Expectation of Success	54
F.	Petitioner Does Not Demonstrate a Reasonable Likelihood of Success on Ground 2	62
G.	Secondary Indicia of Non-Obviousness Further Support the Patentability of the Challenged Claims.....	65
1.	The Prior Art Teaches Away from the Claimed Inventions.....	66
2.	The Claimed Inventions Produced Unexpected Results.....	70
IV.	CONCLUSION.....	74

TABLE OF AUTHORITIES

	<u>Page</u>
Cases	
<i>Abbott Labs., Inc. v. Sandoz, Inc.</i> , 544 F.3d 1341 (Fed. Cir. 2009)	60
<i>Alcon Research, Ltd. v. Watson Labs., Inc.</i> , No. 15-1159, 2018 WL 1115090 (D. Del. Mar. 1, 2018).....	39, 54
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.</i> , 676 F.3d 1063 (Fed. Cir. 2012)	60
<i>Endo Pharm. Inc. v. Actavis LLC</i> , 922 F.3d 1365 (Fed. Cir. 2019)	61
<i>E-One, Inc. v. Oshkosh Corp.</i> , IPR2019-00161, Paper 16 (PTAB May 15, 2019)	8
<i>Honeywell Int’l Inc. v. Mexichem Amanco Holding S.A.</i> , 865 F.3d 1348 (Fed. Cir. 2017)	56
<i>Hospira, Inc. v. Genentech, Inc.</i> , IPR2017-00804, Paper No. 83 (PTAB Oct. 3, 2018)	38, 62
<i>Impax Labs., Inc. v. Lannett Holdings Inc.</i> , 246 F. Supp. 3d 1024 (D. Del. 2017).....	44
<i>Initiative for Meds., Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC</i> , IPR2018-00103, Paper 7 (PTAB June 13, 2018)	44
<i>Initiative for Meds., Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC</i> , IPR2018-00119, Paper 7 (PTAB May 4, 2018)	45
<i>Janssen Pharm., Inc. v. Watson Labs., Inc.</i> , No. 08-5103, 2012 WL 3990221 (D.N.J. Sept. 11, 2012).....	43
<i>Janssen Prods., L.P. v. Lupin Ltd.</i> , 109 F. Supp. 3d 650 (D.N.J. 2014)	39
<i>Leo Pharm. Prods. v. Rea</i> , 726 F.3d 1346 (Fed. Cir. 2013)	38

<i>Luye Pharma Grp. Ltd. v. Alkermes Pharma Ireland Ltd.</i> , IPR2016-01096, Paper 74 (PTAB Nov. 28, 2017)	65
<i>Mylan Pharm., Inc. v. Bayer Intellectual Property GMBH</i> , IPR2018-01143, Paper 13 (PTAB Dec. 3, 2018)	8
<i>E.I. DuPont de Nemours & Co. v. Synvina C.V.</i> , 904 F.3d 996 (Fed. Cir. 2018)	55
<i>NHK Spring Co., Ltd. v. Intri-Plex Techs., Inc.</i> , IPR2018-00752, Paper 8 (PTAB Sept. 12, 2018).....	5, 7, 8
<i>In re O'Farrell</i> , 853 F.2d 894 (Fed. Cir. 1988)	55
<i>Par Pharm., Inc., v. Jazz Pharm. Ireland Ltd.</i> , IPR2016-00002, Paper No. 12 (PTAB Apr. 12, 2016).....	61, 62
<i>Pfizer Inc. v. Apotex Inc.</i> , 480 F.3d 1348 (Fed. Cir. 2007)	57
<i>Pfizer Inc. v. Sandoz Inc.</i> , No. 13-1110, 2016 WL 1611377 (D. Del. Apr. 20, 2016)	66
<i>Sandoz, Inc. v. AbbVie Biotech. Ltd.</i> , IPR2017-01823, Paper No. 16 (PTAB Feb. 9, 2018)	38
<i>In re Stepan Co.</i> , 868 F.3d 1342 (Fed. Cir. 2017)	40, 54, 56
<i>Unified Patents Inc. v. Custom Media Techs. LLC</i> , IPR2015-00516, Paper 9 (PTAB June 25, 2015)	44, 45
<i>Vanda Pharm. Inc. v. Roxane Labs</i> , 203 F. Supp. 3d 412 (D. Del. 2016).....	39, 60

Rules / Statutes

35 U.S.C. § 103	57
35 U.S.C. § 324(a)	1, 5

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.